Aarti Drugs LimitedAARTIDRUGSCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Jun 2026 14 quarters of data

₹396.35

MCap ₹3,617 Cr · P/E 20.3

Aarti Drugs Limited — Stock analysis & AI research Aarti Drugs Limited — Multibagger AI analysis Aarti Drugs Limited — Seasonality — best & worst months Aarti Drugs Limited — Technical indicators & charts Aarti Drugs Limited — Technical setup — score, trend, support & resistance Aarti Drugs Limited — Triple Top pattern broken down ↓ Aarti Drugs Limited — Live exchange announcements

📋 Stocks Cheaper Than Their Industry 📈 SuperTrend Bearish Signal 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹627 Cr

Sales · Jun 2026

+20.4% YoY

₹92 Cr

Operating Profit · Jun 2026

+43.7% YoY

14.6%

OPM % · Jun 2026

+18.7% YoY

₹51 Cr

Net Profit · Jun 2026

+4.5% YoY

₹5.57

EPS · Jun 2026

+4.5% YoY

📝 Aarti Drugs Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Aarti Drugs Limited reported revenue of ₹627 crore for the quarter ended June 2026 (Q1 FY27), up 20.4% from ₹521 crore in the same quarter last year, and down 0.7% sequentially over the March 2026 quarter.

Net profit rose 4.5% year-on-year to ₹51 crore, from ₹49 crore. Earnings per share (EPS) came in at ₹5.57.

Operating profit stood at ₹92 crore — an operating margin (OPM) of 14.6%, compared with 12.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Aarti Drugs Limited posted revenue of ₹2,334 crore, a growth of 7.4% over FY25, with a net profit of ₹176 crore (up 12.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,440 crore with a net profit of ₹178 crore.

Valuation snapshot

At the current price of ₹396.35, AARTIDRUGS has a market capitalisation of ₹3,617 crore and a trailing P/E of about 20.3.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 2nd-largest of the 11 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 54.07%, foreign institutional investors (FIIs) 2.26%, domestic institutional investors (DIIs) 10.24%, public shareholders 33.43% of Aarti Drugs Limited.

Promoter holding slipped from 54.43% to 54.07% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹3,617 Cr

Current Price ?

₹396.4

P/E ?

20.30below ind

Industry P/E ?

32.10

P/B ?

2.57

P/S ?

1.48

P/FCF ?

23.80

Enterprise Value ?

₹4,038 Cr

EV/EBITDA ?

8.34

PEG ?

6.77

Earnings Yield ?

9.5%

Dividend Yield ?

0.49%

Profitability & Returns

Sales (TTM) ?

₹2,440 Cr

OPM ?

19.8%

Profit after tax (TTM) ?

₹178 Cr

EPS (TTM) ?

₹19.52

ROCE ?

12.0%

ROE ?

12.7%

ROA ?

7.5%

Growth

Sales — latest qtr ?

₹627 Cr

PAT — latest qtr ?

₹51 Cr

YoY qtr sales growth ?

20.4%

YoY qtr profit growth ?

4.5%

Sales growth (3y) ?

-3%

Sales growth (5y) ?

Profit growth (3y) ?

Profit growth (5y) ?

-8%

Financial Health

Debt ?

₹421 Cr

Debt to Equity ?

0.30

Interest Coverage ?

7.4

Current Ratio ?

N/A

Ownership

Promoter holding ?

54.07%

Change in promoter holding ?

-1.16%

Pledged percentage ?

N/A

Market

Return 3 months ?

-6.1%

Return 6 months ?

6.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	696	592	578	538	560	493	543	515	623	521	579	602	632	627	+20.4%	-0.7%
Operating Profit	89	72	65	60	69	54	60	60	89	64	75	55	262	92	+43.7%	-65.0%
Other Income	1	1	1	2	1	0	0	11	2	0	0	1	1	0	-48.7%	-82.1%
Interest	8	8	8	7	8	7	7	8	7	7	6	9	26	7	+1.9%	-73.7%
Depreciation	12	12	12	12	12	12	12	12	12	12	14	18	56	15	+24.0%	-72.7%
Profit Before Tax	69	53	47	43	50	35	41	52	71	45	56	29	181	68	+49.9%	-62.6%
Net Profit	53	40	35	32	36	27	30	39	61	49	42	41	45	51	+4.5%	+13.0%
EPS	5.74	4.27	3.75	3.44	3.93	2.93	3.33	4.22	6.74	5.33	4.58	4.44	4.93	5.57	+4.5%	+13.0%
OPM %	12.7%	12.2%	11.3%	11.1%	12.3%	11.0%	11.0%	11.7%	14.3%	12.3%	13.0%	9.1%	41.5%	14.6%	+18.7%	-64.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹2,174 Cr	₹2,334 Cr	₹2,440 Cr	+7.4%
Operating Profit	₹263 Cr	₹456 Cr	₹484 Cr	+73.5%
OPM %	12.10%	19.56%	19.85%	+61.7%
NPM %	7.22%	7.54%	7.30%	+4.4%
Other Income	₹14 Cr	₹3 Cr	₹3 Cr	-79.1%
Depreciation	₹48 Cr	₹99 Cr	₹102 Cr	+108.9%
Interest	₹29 Cr	₹48 Cr	₹49 Cr	+66.1%
EBIT	₹215 Cr	₹357 Cr	₹382 Cr	+65.7%
PBT	₹199 Cr	₹311 Cr	₹334 Cr	+56.4%
Tax	₹32 Cr	₹-1 Cr	₹19 Cr	-102.8%
Net Profit	₹157 Cr	₹176 Cr	₹178 Cr	+12.2%
EPS	₹17.22	₹19.28	₹19.52	+12.0%
Material Cost	₹1,038 Cr	₹1,073 Cr	₹1,175 Cr	+3.4%
Employee Cost	₹62 Cr	₹81 Cr	₹84 Cr	+31.3%
Extraordinary Items	—	—	₹2 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	93	92	91	91	+0.0%
Reserves	1,022	1,083	1,160	1,314	+13.3%
Borrowings	535	475	516	421	-18.4%
Other Liabilities	546	522	506	556	+9.9%
Total Liabilities	2,196	2,172	2,273	2,382	+4.8%
Fixed Assets	634	722	761	971	+27.6%
CWIP	161	222	273	106	-61.2%
Investments	29	30	42	72	+71.4%
Other Assets	1,372	1,198	1,196	1,232	+3.0%
Total Assets	2,196	2,172	2,273	2,382	+4.8%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	162	337	220	254	+15.5%
Cash from Investing Activity	-131	-187	-135	-128	+5.2%
Cash from Financing Activity	-31	-149	-85	-126	-48.2%
Net Cash Flow	0	1	1	0	-100.0%
Free Cash Flow	31	148	83	152	+83.1%
CFO/OP	76%	144%	103%	94%	-8.7%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	117	104	118	118	+0.0%
Inventory Days	102	107	106	102	-3.8%
Days Payable	89	96	97	104	+7.2%
Cash Conversion Cycle	130	115	127	116	-8.7%
Working Capital Days	73	79	79	80	+1.3%
ROCE %	15%	14%	14%	12%	-14.3%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	55.23%	54.72%	55.03%	55.03%	54.43%	54.07%	-0.7%
FIIs	2.26%	2.68%	2.15%	1.57%	1.52%	2.26%	+48.7%
DIIs	9.94%	9.90%	10.12%	10.22%	10.29%	10.24%	-0.5%
Public	32.58%	32.70%	32.71%	33.19%	33.75%	33.43%	-0.9%
No. of Shareholders	1,60,260	1,52,252	1,48,363	1,44,946	1,43,476	1,39,949	-2.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SMSPHARMA SMS Pharmaceuticals	₹442.45	4,144	39.7	898	102	19.3%	11.4%	13.3%	48.6%	5.6%	-1.4%
2	AARTIDRUGS Aarti Drugs	₹428.30	3,909	20.5	2,678	191	12.4%	7.1%	7.5%	16.3%	18.9%	-7.2%
3	HIKAL Hikal	₹229.83	2,834	—	1,734	-34	13.4%	-2.0%	-8.0%	-154.4%	6.0%	67.0%
4	BETA Beta Drugs	₹2,064.90	2,084	37.5	513	57	20.5%	11.2%	—	—	25.5%	31.7%
5	NGLFINE NGL Fine-Chem	₹2,786.60	1,722	30.1	536	57	15.6%	10.6%	36.0%	123.2%	33.6%	99.1%
6	ANUHPHR Anuh Pharma	₹92.99	932	21.1	779	44	8.6%	5.7%	16.5%	-12.8%	4.2%	42.8%
7	INFINIUM Infinium Pharma	₹222.95	347	31.2	190	14	11.3%	7.2%	—	—	45.2%	166.7%
8	AAREYDRUGS Aarey Drugs	₹98.71	329	67.1	415	4	1.6%	1.0%	-0.4%	12.3%	-56.3%	-25.3%
9	PAR Par Drugs	₹128.90	159	10.9	109	14	18.3%	13.3%	2.7%	-1.9%	20.1%	41.6%
10	KREBSBIO Krebs Biochemicals	₹57.94	125	—	25	-14	-10.0%	-55.9%	-45.2%	37.1%	27.4%	53.3%
11	VILINBIO Vilin Bio	₹18.00	27	14.2	42	2	7.6%	4.6%	—	—	215.9%	1680.0%

❓ Frequently asked questions

What was Aarti Drugs Limited's revenue in Q1 FY27?

What was Aarti Drugs Limited's net profit in Q1 FY27?